Viewing nowCombinationJanugriptin Duo XR Extended-release Tablet 50/500 mg
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Sears Pharmaceutical Co., Ltd.

MFDS item code 202300615 · Approved 2023.02.17 · Insurance code 689001770
Improvement of glycemic control in patients with type 2 diabetes
This medication is used to assist patients with type 2 diabetes in controlling their blood sugar levels. It effectively improves blood sugar levels by administering sitagliptin and metformin together to patients who are also following a meal plan and exercise regimen. This medication supports individuals who struggle with blood sugar management in achieving more stable blood sugar control. It helps improve blood sugar control for diabetes management.
In antidiabetic therapy, the dosage of this drug should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug should be taken once daily with a meal, preferably in the evening, and the dosage should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed. Cases have been reported in which the drug was incompletely dissolved and excreted in the feces. It is not known whether the material excreted in the feces contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in the feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this drug 100/1000 mg extended-release tablet once daily. Patients taking this drug 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients with no previous experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin treatment: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient’s current dose of metformin. - Patients switching from concomitant therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. - Patients whose current metformin regimen is an immediate-release tablet at a dose of 850 mg or 1000 mg twice daily may start with this drug 50/1000 mg extended-release tablets at a dose of 2 tablets once daily. 3. Patients who cannot achieve adequate glycemic control with concomitant therapy with metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to assess the safety and efficacy of switching to this drug in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes mellitus may cause changes in glycemic control; caution should therefore be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this drug, because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication is used to treat diabetes and helps control blood sugar levels. During the use of this medication, serious allergic reactions may occur, so if symptoms such as rashes, hives, or difficulty breathing appear, discontinue use immediately and consult a doctor. There is a risk of pancreatitis, which is inflammation of the pancreas, so if symptoms such as abdominal pain, nausea, or vomiting appear, notify a healthcare provider immediately. This medication is not to be used in patients with poor kidney function, and regular kidney function tests should be performed. Particularly, patients with dehydration, serious infections, heart failure, or acute myocardial infarction should not take this medication. When undergoing tests with iodine contrast agents, this medication should be stopped for a certain period before and after the test. Individuals with allergies to the components of this medication should avoid taking it. It is safe for women who are pregnant, potentially pregnant, or breastfeeding to avoid taking this medication. Safety and efficacy have not been sufficiently confirmed for children and adolescents, so it is advisable not to use it in individuals under 18 years of age. This medication can cause hypoglycemia (a state of excessively low blood sugar), so caution is needed when skipping meals or engaging in vigorous exercise. Additionally, when taken with other hypoglycemic agents or insulin, the risk of hypoglycemia may increase, hence dosage adjustments should be made as per the physician’s instructions. Regular monitoring of liver function and vitamin B12 levels in the blood is necessary while on this medication. Excessive drinking or alcohol consumption may increase the risk of side effects from this medication, so it is best to avoid them. In the case of surgery, this medication should be discontinued 48 hours prior to the surgery, and restarted only after kidney function has returned to normal post-surgery. While taking this medication, adhere to a regular meal plan, exercise, and conduct regular blood sugar and kidney function tests to maintain good health. If a dose is overdosed, seek medical attention immediately for appropriate treatment, as some components can be removed via dialysis.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to avoid exposure to air and moisture, and it is safe to store at room temperature between 1 and 30 degrees Celsius. Proper storage helps maintain the effectiveness of the medication and prevents deterioration.
Light blue, oval, bi-convex extended-release film-coated tablet
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Sears Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.